Navigation Links
MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR
Date:10/9/2007

ted States. The PROVECTOR geographically eradicates the problem while preventing negative impact within the ecosystem.

William C. Parker, Chief Executive Officer of MIT Holding, Inc., said, This is a major breakthrough in stopping the spread of infectious disease such as malaria, dengue, and the West Nile virus. Our goal in developing this product is to address and help alleviate the four major problems surrounding mosquito-carrying infectious disease: occurrence of drug-resistant malaria, absence of a vaccine for dengue, population of insecticide resistant mosquitoes, and the current cost of malaria and dengue control. The PROVECTOR device can be used both within households and outdoors and is intended to be available at an affordable price, reducing the financial burden that current treatments often carry. Working in tandem with MEVLABS and Georgia Southern University, MIT Holding is honored to be at the forefront of developing the PROVECTOR, a possible solution to the growing, devastating, worldwide problems that these infectious diseases inflict on the global population.


'/>"/>

Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
MIT Holding/Mevlabs
Source:Eurekalert

Page: 1 2

Related biology news :

1. Georgia Tech accelerates drug discovery with new IBM supercomputing cluster
2. Scientists journey to southern Africa to unravel the secret world of elephant communication
3. New Species of Coral Discovered Off Southern California
4. High carbon dioxide levels spur Southern pines to grow more needles
5. Genetically modified maize not found in southern Mexico
6. Oldest dated evidence of cattle in southern Africa found
7. High levels of blindness in southern Sudan following years of war
8. Massive herds of animals found to still exist in Southern Sudan
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. Biomarkers isolated from saliva successfully predict oral and breast cancer
11. UN successfully tests green pesticide against locusts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... groundbreaking payment method. Payment accounts may be selected via ... accessed if both the speech (the word associated with ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... make a vaccine to protect against 2009 influenza A (H1N1) ... process for future flu seasons. The goal is to shorten ... manufacture the vaccines for them. In a paper ... & Selection , Rice researchers described a new method to ...
... PARK, PAOzone, the main component of air pollution, or ... oxygen reacts with other chemicals. Although ozone pollution is ... infiltrates indoor environments like homes and offices. Ozone can ... lights, and some electrostatic air purification systems, all of ...
... genes can reveal not only the "lifestyle" of marine microbes ... finding means researchers may be able to predict the types ... the genomes of just a few dominant species, according to ... Wales. As well, it may reveal new insights into the ...
Cached Biology News:Rice researchers seek better vaccine procedure 2Rice researchers seek better vaccine procedure 3Houseplants cut indoor ozone 2Genomes reveal bacterial lifestyles: Research 2
(Date:3/4/2015)... REDWOOD CITY, Calif. , March 4, 2015 ... ACRX ), a specialty pharmaceutical company focused on ... the treatment of acute and breakthrough pain, today ... yearly 2014 financial results after market close on ... an investment-community conference call at 4:30 p.m. Eastern ...
(Date:3/4/2015)... -- Launched by the Assistance Publique ... December 2011, ,SARAH, - the French national collaborative ... in advanced hepatocellular carcinoma (HCC) has enrolled more than ... SARAH, a large French study of patients with advanced, ... completed patient enrolment, exceeding its 400-patient target, according to ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has announced ... - 2025" report to their offering. ... extensive study on the marketed and pipeline gene therapies. ... this field for over a decade but there are ... one approved in the EU). There are many promising ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... Jan. 12, 2012  Inverseon, Inc., a pharmaceutical company developing ... that while it anticipates that its asthma program will ... cessation as the initial indication for INV102. ... smoking cessation, and also an inhaled COPD program, makes ...
... ANNAPOLIS, Md., Jan. 11, 2012 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that Eric I. ... Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, ... Room/Room 2 at the Hard Rock Hotel, Hollywood Florida.  ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Inverseon Focuses on Mucous and Smoking Cessation 2PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Recombinant Human PTP1B (aa 2-321), CF...
Biology Products: